Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists test safer treatment for equine melanoma
grey horse
Current treatments for melanoma - particularly cisplatin - carry health risks for both horse owners and vets.

Study shows promising results

German scientists have found a promising anti-cancer treatment for horses with melanoma.


A study published in the journal Chemico-Biological Interactions found that Betulinic acid could become an effective and safer treatment for equine melanoma compared to current treatments.

The drug, found in the bark of the white birch, is already used for treating melanomas in humans.


Speaking to The Horse magazine, Dr Richard Paschke of Martin Luther University, Germany, said that he was "optimistic" that this could be the new cure for skin cancer in horses.

Betulinic acid slows down the growth of cancer cells by breaking down the membranes of the mitochondria (the cell’s energy factory). If a cancer cell’s mitochondria stops working, it lacks energy and will eventually die.


In their study, researchers tested Betulinic acid and its two derivatives on two equine melanoma cell lines.

The researchers found that all three cell lines led to the death of both cell lines, mostly within 24-48 hours of treatment.
The most effective compound was NVX-207 which showed high cytotoxicity on both equine melanoma cell lines.

The researchers then tested the drug in two grey horses to make sure that equines could handle the treatment safely and without any serious side effects.

According to Dr Paschke, regular clinical observation and blood tests showed that it was "well tolerated".

Current treatments for melanoma - particularly cisplatin - carry health risks for both horse owners and vets. Human exposure to the drug can result in kidney problems and allergic reactions.

The researchers say that the next step is to test the efficacy of Betulinic acid on a large group of horses affected with melanoma.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.